Your browser doesn't support javascript.
loading
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Johnson, Brett E; Mazor, Tali; Hong, Chibo; Barnes, Michael; Aihara, Koki; McLean, Cory Y; Fouse, Shaun D; Yamamoto, Shogo; Ueda, Hiroki; Tatsuno, Kenji; Asthana, Saurabh; Jalbert, Llewellyn E; Nelson, Sarah J; Bollen, Andrew W; Gustafson, W Clay; Charron, Elise; Weiss, William A; Smirnov, Ivan V; Song, Jun S; Olshen, Adam B; Cha, Soonmee; Zhao, Yongjun; Moore, Richard A; Mungall, Andrew J; Jones, Steven J M; Hirst, Martin; Marra, Marco A; Saito, Nobuhito; Aburatani, Hiroyuki; Mukasa, Akitake; Berger, Mitchel S; Chang, Susan M; Taylor, Barry S; Costello, Joseph F.
Afiliação
  • Johnson BE; Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
  • Mazor T; Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
  • Hong C; Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
  • Barnes M; Department ofPathology, University of California San Francisco, San Francisco, CA, USA.
  • Aihara K; Genome Science Laboratory, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
  • McLean CY; Department of Neurosurgery, University of Tokyo, Tokyo, Japan.
  • Fouse SD; Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
  • Yamamoto S; Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
  • Ueda H; Genome Science Laboratory, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
  • Tatsuno K; Genome Science Laboratory, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
  • Asthana S; Genome Science Laboratory, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
  • Jalbert LE; Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Nelson SJ; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Bollen AW; Department ofBioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
  • Gustafson WC; Department ofBioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
  • Charron E; Department ofRadiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
  • Weiss WA; Department ofPathology, University of California San Francisco, San Francisco, CA, USA.
  • Smirnov IV; Department ofPediatrics, University of California San Francisco, San Francisco, CA, USA.
  • Song JS; Department ofNeurology, University of California San Francisco, San Francisco, CA, USA.
  • Olshen AB; Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
  • Cha S; Department ofPediatrics, University of California San Francisco, San Francisco, CA, USA.
  • Zhao Y; Department ofNeurology, University of California San Francisco, San Francisco, CA, USA.
  • Moore RA; Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
  • Mungall AJ; Department ofEpidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
  • Jones SJM; Institute for Human Genetics, University of California San Francisco, San Francisco, CA, USA.
  • Hirst M; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.
  • Marra MA; Department ofEpidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
  • Saito N; Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
  • Aburatani H; Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Mukasa A; Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Berger MS; Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Chang SM; Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Taylor BS; Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Costello JF; Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, BC, Canada.
Science ; 343(6167): 189-193, 2014 Jan 10.
Article em En | MEDLINE | ID: mdl-24336570
ABSTRACT
Tumor recurrence is a leading cause of cancer mortality. Therapies for recurrent disease may fail, at least in part, because the genomic alterations driving the growth of recurrences are distinct from those in the initial tumor. To explore this hypothesis, we sequenced the exomes of 23 initial low-grade gliomas and recurrent tumors resected from the same patients. In 43% of cases, at least half of the mutations in the initial tumor were undetected at recurrence, including driver mutations in TP53, ATRX, SMARCA4, and BRAF; this suggests that recurrent tumors are often seeded by cells derived from the initial tumor at a very early stage of their evolution. Notably, tumors from 6 of 10 patients treated with the chemotherapeutic drug temozolomide (TMZ) followed an alternative evolutionary path to high-grade glioma. At recurrence, these tumors were hypermutated and harbored driver mutations in the RB (retinoblastoma) and Akt-mTOR (mammalian target of rapamycin) pathways that bore the signature of TMZ-induced mutagenesis.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Antineoplásicos Alquilantes / Dacarbazina / Glioma / Recidiva Local de Neoplasia Limite: Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Antineoplásicos Alquilantes / Dacarbazina / Glioma / Recidiva Local de Neoplasia Limite: Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article